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PREDICTING HEALTHCARE EXPENDITURES AND UTILIZATION IN PATIENTS
WITH DYSLIPIDEMIA USING THE UPDATED CHARLSON COMORBIDITY INDEX
(CCI) AND PRIOR EXPENDITURES
Cheng LI, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To assess the utility of the updated Charlson Comorbidity Index (CCI)
and prior utilization for the prediction of healthcare expenditures and utilization in
patients with dyslipidemia. METHODS: Data were retrieved from the Medical Ex-
penditure Panel Survey (MEPS) Panel 12 (2007-2008) for this retrospective cohort
study. Annual healthcare expenditures, the original CCI (CCI-1), and the updated
CCI (CCI-2) scores were calculated for patients who had dyslipidemia in 2007. Ad-
justed R2 from linear regression models were used for the estimation of log-trans-
formed healthcare expenditures (COST) in 2008. C statistics from logistic regression
models were used to compare the predictive power in the risk of hospitalizations (
1 admission), risk of emergency department visits ( 1 visit), and high expenditures
( 90th percentile of COST) in 2008. RESULTS: The cohort included 1,751 patients
with dyslipidemia. The mean (SD) age was 60.7 (14.0) years, and 52% were female.
Log-transformed prior-year expenditures showed better power than the CCI-1 or
CCI-2 in predicting log-transformed COST (adjusted R2  22.4% vs. 13.2% or 14.4%)
and individuals incurring  90th percentile of COST (c  0.779 vs. 0.690 or 0.704).
The CCI-2 was a better predictor of the risk of hospitalizations and the risk of
emergency department use (c 0.674, 0.644) than either the CCI-1 (c 0.660, 0.629)
or log-transformed prior-year expenditures (c  0.667, 0.624). CONCLUSIONS: In a
U.S. nationally representative sample of patients with dyslipidemia, prior-year
expenditures appeared to be the best predictor of future healthcare expenditures,
but the updated CCI was a better predictor of the risk of hospitalizations or emer-
gency department use. Compared with the original CCI, the updated CCI showed
improved predictive performance.
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HOW HAVE QUALITY CHECKLISTS IMPROVED THE QUALITY OF PUBLISHED
ECONOMIC EVALUATIONS? AN EXAMPLE OF VENOUS THROMBOEMBOLISM
(VTE) PROPHYLAXIS
Yoshida E1, Plich A1, Toumi M2
1Creativ-Ceutical Ltd., London, UK, 2University Claude Bernard Lyon1, Lyon, France
OBJECTIVES: Standard quality checklists for economic evaluation (EE) exist and are
referred to by journal editors. In addition, there are country- and disease-specific EE
guidelines available. We examined if the existence of these checklists and guide-
lines improve the quality of published EE. METHODS: The evaluation was per-
formed for a single therapeutic area, VTE prophylaxis in total hip and knee replace-
ment, to ensure that the studies and interventions were comparable. A systematic
review of published literature written in English was conducted using EMBASE,
Medline, Cochrane Library, NHS EED, Econlit in July 2010. A number of EE parame-
ters were extracted from each eligible publication, and were analysed over time.
The impact of the VTE specific EE guidelines on the quality of published EEs was
assessed. A subset of the articles for the UK were evaluated in regards to their
adherence to the Drummond quality checklist as well as to the selected items of the
NICE reference case. RESULTS: Sixty-seven articles were selected for the review,
including 13, 24, 23 and 7articles in the year 1996, 19962000, 20012005 and
2005, respectively. The quality of EEs had generally advanced over time: the time
horizon increased, models became more sophisticated, and probabilistic sensitiv-
ity analysis was used more frequently. There was a sense of improvement regard-
ing the quality of published EEs after the introduction of the VTE-specific EE guide-
lines, although a number of recent publications did not refer the guidelines. Few
quality requirements from the Drummond checklist were not addressed in the
eight UK-specific publications. The adherence to the NICE reference case among
the latest UK publications was high. CONCLUSIONS: It is questionable whether the
quality checklists have contributed any significant improvements to the quality of
published EEs. And so there is a need to strengthen the awareness of editors on the
availability of the quality checklists and guidelines for EE.
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FRAMINGHAM RISK SCORE IN HEALTH ECONOMIC MODELLING: A EUROPEAN
PERSPECTIVE
Carlqvist P1, Hermansson J2, Moorcroft E3, Hettle R3
1Heron AB, Stockholm, Stockholm, Sweden, 2Heron AB, Stockholm, Sweden, 3HERON Evidence
Development Ltd, Luton, UK
OBJECTIVES: Many clinical practice guidelines recommend that providers and pa-
tients base their treatment decisions regarding coronary heart disease (CHD) pre-
vention on the assessment of underlying risk. The need to predict the risk of an
event in CHD is of importance when modelling the cost-effectiveness of lipid-
modification therapies where the outcome is determined by the risk of a CHD event
and the change in risk due to the intervention. Risk score equations have been
derived from cohort studies or randomised trials and usually estimate the risk of
having a CHD event over 5 to 10 years. The Framingham risk score (FRS) is the most
famous and used risk calculator and its many adaptations are used to predict the
risk for very different populations. In this study we investigate FRS’s development
into a global tool to estimate CHD events, focussing on its use in health economic
modelling to demonstrate the efficacy of lipid modifying therapies in European
populations.METHODS:A systematic search was undertaken in Embase to identify
European health economic studies using FRS. The studies where assessed for in-
formation about the implementation of the FRS and any results of the validation of
the predicted risk. RESULTS: There exist several studies employing the FRS to
evaluate the cost-effectiveness of interventions for CHD. However, the Framing-
ham cohort differs from many groups to which it has been applied. There have
been several attempts to recalibrate FRS to better its performance toward European
populations with varying success. CONCLUSIONS: The Framingham risk score is
still used in a European setting, even if it is often criticised to misrepresent the CHD
risk. There are alternative risk functions, developed in order to better accommo-
date the risk of specific European populations. However, the use of FRS seems to
still be a valid option for a Global or pan-European perspective.
PCV148
MULTIPLE PROPENSITY SCORE ANALYSIS TO ESTIMATE TREATMENT EFFECTS
IN PATIENTS WITH HEART FAILURE
Chitnis AS, Aparasu RR, Chen H, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: Propensity scores (PS) are often used with binary treatments. How-
ever, in day to day practice multiple treatment options are often available. There-
fore extension of binary propensity analysis to multiple PS will add to the empirical
knowledge of use of PS. We used multiple PS to determine an association of indi-
vidual angiotensin -converting enzymes inhibitors (ACEIs) on heart failure (HF) –
hospitalization to illustrate the use of multiple PS. METHODS: The study was a
retrospective analysis of a national cohort of patients diagnosed with HF identified
from the Department of Veterans Affairs electronic medical records system. Mul-
tiple PS analysis was used to balance 47 baseline patient characteristics between
the different ACEIs. Multiple PS were obtained from multinomial logistic regres-
sion. Effect of different ACEIs on time to HF-hospitalization was assessed using a
multiple propensity weighted Cox proportional hazard model. Captopril was used
as reference group. RESULTS: The study included 139,998 patients with 69.50%
(97,293) on lisinopril, 21.79 % (30,503) on fosinopril, 8.41% (11,775) on captopril, and
0.30% (423) on enalapril. Multiple PS balanced nearly all differences between ACEIs
groups. The adjusted hazards ratio from multiple PS-weighted Cox models were
0.800 (95% CI: 0.492-1.297) for enalapril, 0.971 (95% CI: 0.877-1.074) for fosinopril,
and 1.005 (95% CI: 0.918-1.101) for lisinopril compared with captopril.
CONCLUSIONS: We found no difference between four ACEIs in reducing the risk of
HF-hospitalization. The use of multiple PS is a straightforward approach when
comparing multiple treatments.
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INCIDENCE AND COST OF TREATMENT-EMERGENT COMORBID EVENTS IN AN
INSURED POPULATION RECEIVING TREATMENT FOR CHRONIC HEPATITIS C
(CHC) VIRUS INFECTION
Sapra S1, Chang E2, Broder M2, L’Italien G1
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Partnership for Health Analytic Research, LLC,
Beverly Hills, CA, USA
OBJECTIVES: To estimate the incidence of treatment-emergent comorbid events
and incremental costs of treating these events in insured patients initiating pegy-
lated interferon alfa (peg-alfa) and ribavirin (RBV) treatment for CHC.METHODS: In
a retrospective cohort analysis of healthcare claims from a US insurer, we studied
CHC patients newly treated with peg-alfa/RBV between 2006-2008 and continu-
ously eligible for 12 months before/after treatment initiation. Treatment-emergent
comorbid events were defined by new medical/pharmacy claims for predefined
conditions in the 12 months after treatment initiation. The net incremental cost of
treatment-emergent comorbidities was calculated as the difference between base-
line and follow-up costs for these comorbidities and their treatment, excluding
cost of peg-alfa/RBV. Baseline measures including age, gender, and region were
used in a multivariate model to identify factors associated with treatment-emer-
gent comorbid event charges.RESULTS:Of 3795 newly treated patients, 1269 (mean
age50.2 [SD 7.7], 36.2% female) met the selection criteria. The mean cost of peg-
alfa/RBV treatment was $25,612 (SD $13,289). New treatment-emergent events
were common, with 61.6% of patients having  1 event. Anemia was identified in
29.2% of patients, fatigue in 16.4%, depression in 11.5%, and neutropenia in 10.9%.
The mean incremental cost for the pre-defined treatment-emergent comorbid
events in the post-index period was $6,377 (SD $22,326); $2,783 for medical and
$3,595 for pharmacy claims. Age  60 and female gender were significantly asso-
ciated with higher charges in the multivariate model.CONCLUSIONS: In an insured
US cohort with CHC, treatment-emergent comorbidities with peg-alfa/ RBV were
common and increased cost by $6000/treated patient. This excludes indirect costs
and is therefore a conservative estimate. Costs might increase with the use of triple
therapy with peg-alfa/RBV and a protease inhibitor, as additional treatment-emer-
gent co-morbid events may be expected. Better-tolerated therapies that reduce the
financial burden on the health care system costs and improve patient experience
are desirable.
PGI2
THE RELATIONSHIP BETWEEN ACUTE AND CHRONIC ACETAMINOPHEN
EXPOSURE AND LIVER TOXICITY
Gokhale MN1, Foster HR1, Cleves M2, Hogan WR2, James LP2, Martin B1
1University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA,
2University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR, USA
OBJECTIVES: The relationship between acute high dose acetaminophen and hep-
atotoxicity is well established, however little is known about the relationships with
chronic acetaminophen ingestion. This study sought to determine the associations
between acute and chronic prescription acquired acetaminophen use and
hepatotoxicity. METHODS: This was a retrospective case control study of a 10%
random sample of the Pharmetrics LifeLink commercial claims data from 1997-
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